SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is trending as a potential solution to increase transaction speeds and enhance regulatory compliance in blockchain, with some community members suggesting it could complement larger crypto projects like NVDA, SUI, and BTC. Its focus on institutional financial infrastructure and integrations with companies like Stripe are also key talking points. However, some users express concern regarding the project.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp ($UAMY) is trending as conversations revolve around its potential role in securing domestic antimony supply, a critical mineral for defense and technology. Community members are discussing the company's contracts with the U.S. military, its production capacity, and potential government support or stake. Some are speculating about a potential merger or acquisition with other materials companies, while others debate the company's valuation and future prospects.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending as investors evaluate its solid earnings and future growth potential, particularly after its recent Nasdaq listing announcement and focus on e-commerce and AI integration. The community is discussing the stock's defensive qualities amid broader market uncertainty, with some analysts raising price targets. Conversations also highlight Walmart's potential competition with Amazon and its impact on smaller retailers.

Avalanche is a high throughput smart contract blockchain platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is trending as community members discuss its potential alongside emerging Layer 1 solutions like Keeta, particularly regarding high-throughput capabilities and institutional adoption. Community talking points highlight Avalanche's subnet architecture versus Keeta's focus on compliance-ready financial infrastructure. Keeta's integration with Stripe's Bridge for fiat on/off-ramps is also sparking interest as a catalyst for institutional flows.

Americas Gold & Silver Corp. engages in the acquisition, exploration, development, and exploration of mineral resource properties. It operates through the following segments: Cosalá Operations, Galena Complex, Relief Canyon, and Corporate and Other. The Cosalá Operations segment operates in Mexico. The Galena Complex and Relief Canyon segments focuses on the United States. The company was founded by Peter Jude Hawley on May 12, 1998 and is headquartered in Toronto, Canada.

Americas Gold and Silver Corp

Americas Silver Corp

Americas Silver Corp is trending as silver prices surge, sparking discussions about the company's potential growth and profitability. Community members are focused on its antimony production and the possibility of government funding, as well as speculation regarding future mergers and acquisitions. The rising silver prices and the company's strategic positioning are creating optimism about its long-term prospects.

Advisorshares Trust - AdvisorShares MSOS 2x Daily ETF

AdvisorShares MSOS Daily Leveraged ETF

MSOX is trending as traders discuss the potential impact of cannabis rescheduling, with some citing Trump's recent comments as a possible catalyst. The community is weighing the risks and rewards of this leveraged ETF, with many expressing confidence in a sector-wide rally. However, some traders remain cautious, pointing to historical volatility and potential reverse splits.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FCEL is trending as investors discuss its potential role in powering AI data centers using natural gas and carbon capture technology, particularly following positive mentions from ExxonMobil's recent earnings call. Community members are weighing the company's prospects against competitors like Bloom Energy, with some anticipating significant upside if FCEL secures major contracts in the expanding AI energy market. Discussions also include the stock's volatile history and the impact of past dilutions on its current valuation.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending amid speculation around potential cannabis rescheduling, with investors awaiting news from the Supreme Court and keeping an eye on Trump's next move. Community members are discussing the potential impact of rescheduling on profitability and institutional investment, while also debating which cannabis companies stand to benefit most. The conversation is also focused on the sector's history of volatility and the potential for a significant rally if rescheduling occurs.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending amid discussions about its role in AI data centers, particularly in relation to Nvidia. Community members are weighing its potential for growth in high-power markets and noting its partnerships. Some traders are closely watching for a breakout, while others express concerns about revenue and insider selling.

Kodiak AI, Inc. is a provider of AI-powered autonomous vehicle technology designed to help tackle some of the toughest driving jobs. Its solutions address the critical problem of safely transporting goods in the face of unprecedented supply chain challenges. The company was founded in 2018 and is headquartered in Mountain View, CA.

Kodiak AI Inc.

Kodiak AI Inc. - Ordinary Shares - Class A

Kodiak AI (KDK) is trending as investors discuss potential short squeezes, low float, and high borrow fees, while also awaiting upcoming earnings and potential news catalysts.  Community members are pointing to analyst upgrades, government contracts, and institutional interest, including recent activity from ARK Invest, as reasons for optimism.  Some are also highlighting the company's position in the autonomous trucking sector and comparing it to competitors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MiNK Therapeutics (NASDAQ:INKT) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded shares of MiNK Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Average Recommendation of "Hold" from Brokerages

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) have received a consensus rating of "Hold" from the five ratings firms that are presently covering the stock, Marketbeat reports. One...

MiNK Therapeutics (NASDAQ:INKT) Posts Earnings Results, Beats Expectations By $0.21 EPS

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts' consensus...

Analysts Offer Predictions for INKT Q1 Earnings

MiNK Therapeutics, Inc. (NASDAQ:INKT - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for MiNK Therapeutics in a research note issued on...

New Strong Sell Stocks for August 22nd

INKT, MNR and CSIQ have been added to the Zacks Rank #5 (Strong Sell) List on August 22, 2025.

MiNK Therapeutics stock falls after William Blair downgrade

Investing.com -- MiNK Therapeutics (NASDAQ:INKT) stock fell 30% on Monday, paring a massive 730% gain from Friday after William Blair downgraded the shares following the spectacular rally.

Shares of MiNK Therapeutics, Inc. (INKT) skyrocketed on Friday following the publication of a case from its clinical trial describing a complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer following treatment with its cell therapy.<a href="https://stocktwits.com/symbol/INKT">INKT shares</a> were up about 466% at the time of writing.The patient had progressed after multiple lines of therapy, including platinum-based chemotherapy, autologous stem cell transplant, and multiple immune checkpoint inhibitors.However, they had complete clinical, radiologic, and biochemical remission, with no evidence of disease over two years later, after receiving a single infusion of agenT-797 alongside the cancer drug nivolumab.AgenT-797 is an off-the-shelf, cryopreserved invariant natural killer T (iNKT) cell therapy. It utilizes iNKT cells, which contribute to anti-tumor effects, from a healthy donor to treat a recipient.Donor iNKT cells were detectable up to six months post-infusion in the patient, and treatment was well-tolerated with no cytokine release syndrome (CRS) or graft-versus-host disease (GVHD).“These findings are part of a growing body of clinical evidence supporting the potential of agenT-797 in solid tumors,” the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.minktherapeutics.com/news-releases/news-release-details/mink-therapeutics-announces-publication-complete-remission">said</a>.AgenT-797 is currently in clinical development for graft-versus-host disease (GvHD), solid tumors, and severe pulmonary inflammation. The company said that its ongoing mid-stage trial in gastric cancer is actively enrolling, with data readouts expected in the coming months.On Stocktwits, retail sentiment around INKT jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1364/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_11_at_9_59_40_AM_png_9597d54c42.webp" alt="INKT's Sentiment Meter and Message Volume as of 10 a.m. ET on July 11, 2025 | Source: Stocktwits" width="1364" height="130"><figcaption>INKT's Sentiment Meter and Message Volume as of 10 a.m. ET on July 11, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the company would have a share offering in the evening as it “absolutely” needs more money.<stembedurl>https://stocktwits.com/pow7904/message/620632189</stembedurl>MiNK ended the first quarter with a cash balance of $3.2 million.INKT stock is up by about 519% this year and by about 345% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/levi-stock-surges-after-analysts-raise-price-target-on-stock-retail-sentiment-extremely-bullish/ch8cXLQR5ZF">Levi Stock Surges After Analysts Raise Price Target On Stock, Retail Sentiment ‘Extremely Bullish’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

MiNK Therapeutics Stock Soars On Patient Receiving Full Remission In Testicular Cancer With Investigational Cell Therapy

“These findings are part of a growing body of clinical evidence supporting the potential of agenT-797 in solid tumors,” the company said.

Equity

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.

Current Price	$12.42
Prev Close	$12.55
Open	$12.69
Dividend Yield	0.00%
50-Day Moving Average	$13.10
Beta	0.53
Avg. Volume	20,594.47
PE Ratio	-4.09

52-Week High	$76.00
52-Week Low	$4.56
Market Capitalization	$58.91M
EPS (Annual)	-$2.86
Price to Book	-4.23
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

INKT
MiNK Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest INKT News

INKTMiNK Therapeutics Inc